Mauna Kea Technologies: publication of positive results in the context of a randomized controlled trial in the field of diffuse interstitial lung disease

(Boursier.com) — Mauna Kea Technologies, the inventor of Cellvizio, the multidisciplinary miniprobe and needle confocal laser endomicroscopy (p/nCLE) platform, today announces the publication in the peer-reviewed journal Respiration of positive results from a large randomized controlled trial that demonstrate that Cellvizio is more precise and safe for guiding transbronchial cryobiopsy than fluoroscopy, enabling improved diagnosis of interstitial lung disease (ILD).

In a first-of-its-kind study1 posted online on September 27, 2023, doctors from the Respiratory Center of the Second Affiliated Hospital of Xiamen Medical College, located in Xiamen, China, unveiled a significant advance in the diagnosis of diffuse interstitial lung disease thanks to combined application of confocal laser endomicroscopy (CLE) and transbronchial cryobiopsy (TBCB).

The study carried out between January and November 2022 included 80 patients with undiagnosed ILD requiring a biopsy. Patients were divided into two randomized groups, one using the Cellvizio and the other using fluoroscopy to guide the transbronchial cryobiopsy device.
Remarkably, the CLE group showed a significantly higher diagnosis rate (95% versus 80%), as well as a 30% reduction in operation time, a 45% reduction in bleeding, and most notably a much lower incidence of pneumothorax (0% versus 25%), compared to the group using fluoroscopy.

“Transbronchial cryobiopsy is becoming an essential tool in the diagnosis of diffuse interstitial lung disease and is experiencing significant growth throughout the world. These new results from a large randomized controlled trial demonstrate that the use of Cellvizio to guide the Transbronchial cryobiopsy not only improves the accuracy of the diagnosis of diffuse interstitial lung disease, but also guarantees a much safer and more effective procedure for patients, thus paving the way for significant new market prospects in the field of interventional pulmonology. ” said Sacha Loiseau, Ph.D., CEO and founder of Mauna Kea Technologies. “We are proud to see the impact of our Cellvizio platform in improving the diagnosis and management of diffuse interstitial lung disease, a set of pathologies that affect millions of people around the world.”